Year 2021 / Volume 113 / Number 12
Letter
Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center

858-859

DOI: 10.17235/reed.2021.8397/2021

Asuncion Ojeda Gómez, Lucía Madero Velázquez, Lidia Buendía Sanchez, Irene Pascual Sánchez, Estefanía Pérez Rabasco, Ana García Monsalve, José Antonio González Ferrández, Mariana Fe García Sepulcre,

Abstract
Secukinumab is a monoclonal antibody that inhibits interleukin-17A. It is currently prescribed for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis, which are immune-mediated diseases that show significant co-heritability with inflammatory bowel disease (IBD). Although this treatment appears to be well tolerated by patients, several cases of new-onset IBD after secukinumab have been reported during the last years.
Share Button
New comment
Comments
No comments for this article
References
1. Fauny M, Moulin D, D'Amico F et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020 Sep;79(9):1132-1138. doi: 10.1136/annrheumdis-2020-217927.
2. Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019 Apr;78(4):473-479. doi: 10.1136/annrheumdis-2018-214273.
3. Rodríguez R, Vázquez JM, Pallarés H. Debut de colitis ulcerosa en contexto de tratamiento con secukinumab: ¿los anti-IL-17A pueden ser un factor desencadenante para la aparición de la enfermedad inflamatoria intestinal? Rev Esp Enferm Dig 2019:111(9):720-721 DOI: 10.17235/reed.2019.5841/2018
4. Fries W et al. Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response? Clin Drug Investig. 2019 Aug;39(8):799-803. doi: 10.1007/s40261-019-00803-7
5. Burisch J et al Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS One. 2020 May 27;15(5):e0233781. doi: 10.1371/journal.pone.0233781
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Citation tools
Ojeda Gómez A, Madero Velázquez L, Buendía Sanchez L, Pascual Sánchez I, Pérez Rabasco E, García Monsalve A, et all. Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center. 8397/2021


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1236 visits.
This article has been downloaded 222 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 14/10/2021

Accepted: 18/10/2021

Online First: 26/10/2021

Published: 09/12/2021

Article Online First time: 12 days

Article editing time: 56 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology